Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084856 | 0.84 | P2RX7 (0.58) | P2RX7NPC1RAB9A | |
| SCHEMBL6084070 | 0.80 | CNR2 (0.57) | ALDH1A1GAAMAPTHPGDHDAC8 | |
| SCHEMBL3021583 | 0.78 | P2RX7 (0.57) | P2RX7ALDH1A1 | |
| SCHEMBL1879183 | 0.75 | HDAC8 (0.52) | KDM4CALDH1A1GAAMAPTHPGD | |
| SCHEMBL3454922 | 0.75 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL10288646 | 0.74 | ALDH1A1 (0.74) | KDM4CALDH1A1GAAMAPTHPGD | |
| SCHEMBL1742676 | 0.73 | KDM4C (0.69) | KDM4CALDH1A1GAAMAPTHPGD | |
| SCHEMBL5095301 | 0.73 | ALDH1A1 (0.73) | KDM4CALDH1A1GAAMAPTHPGD | |
| SCHEMBL22819412 | 0.73 | KDM4C (0.69) | KDM4CALDH1A1GAAMAPTHPGD | |
| SCHEMBL8121085 | 0.73 | P2RX7 (0.64) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | claimed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | claimed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 554/4885KDM4C 4096/4885ALDH1A1 117/4885 |
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 732/4885KDM4C 4246/4885ALDH1A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.